Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio - Seite 3

The clonoSEQ Assay is a single-site test performed at Adaptive Biotechnologies. In addition to its FDA-cleared uses, clonoSEQ is also available as a CLIA-validated laboratory developed test (LDT) service for use in other lymphoid cancers and sample types.  For important information about the FDA-cleared uses of clonoSEQ, including the full intended use, limitations, and detailed performance characteristics, please visit www.clonoSEQ.com/technical-summary.

About the immunoSEQ Assay
The immunoSEQ Assay is the industry gold standard in immunosequencing and helps researchers make discoveries in areas such as oncology, autoimmune disorders, infectious diseases, neurobiology, transplant, and basic immunology. The immunoSEQ Technology is a quantitative and sensitive immunosequencing solution for academic researchers and pharmaceutical companies to understand the immune response to diseases and therapeutics by sequencing the DNA of immune receptors at high throughput scale. The immunoSEQ T-MAP COVID offering is the first and only service of its kind to accurately and reproducibly assess the T-cell immune response to COVID-19 vaccines in development and longitudinally track the persistence of that response over time.

The immunoSEQ Assay can identify millions of T- and B-cell receptors from a single sample in exquisite detail. Offered as a Service or Kit, the immunoSEQ Assay is used to ask and answer translational research questions and discover new prognostic and relevant signals in clinical research. The immunoSEQ Assay provides quantitative, scalable, and reproducible sequencing results along with access to a powerful, easy-to-use analysis tools via the immunoSEQ Analyzer software. The immunoSEQ Assay is for research use only and is not for use in diagnostic procedures. For more information visit us at www.immunoseq.com

About Labcorp
Labcorp is a leading global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. Through our unparalleled diagnostics and drug development capabilities, we provide insights and accelerate innovations to improve health and improve lives. With more than 75,000 employees, we serve clients in more than 100 countries. Labcorp (NYSE: LH) reported revenue of $14 billion in FY2020. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.